However, after 18 – 36 months of treatment, the androgen receptor (AR) signaling pathway is reactivated in the majority of patients, inevitably progressing to castration-resistant prostate cancer (CRPC), which makes prostate cancer much more aggressive and lethal (86). The gene discussed is AR; the disease is prostate carcinoma.